Results 301 to 310 of about 10,236,148 (357)

l-dopa and pancreatic secretion

Biochemical Pharmacology, 1973
Abstract Greengard , Roback and Ivy (1942) first observed that epinine ( N -methyldopamine), dopamine (dihydroxyphenylethylamine) and few phenylethylamine derivatives given intravenously stimulated the canine pancreatic secretion, while the majority of sympathomimetic amines tested inhibited it.
KOROKU HASHIMOTO, YASUHIKO FURUTA, KAZUHIKO IWATSUKI   +2 more
openaire   +1 more source

Electroenzymatic synthesis of l-DOPA

Journal of Biotechnology, 2010
Parkinson's disease is caused by a deficiency of the neurotransmitter dopamine. Since l-DOPA (l-3,4-dihydroxyphenylalanine) is a precursor of dopamine and can pass across the blood-brain barrier, it has been used as a treatment for Parkinson's disease.
Kyoungseon, Min, Don-Hee, Park, Young Je, Yoo   +2 more
openaire   +2 more sources

Effect of L‐Dopa on Polycythemia

Journal of the American Geriatrics Society, 1977
ABSTRACT A patient with Parkinson's disease, in whom polycythemia vera was known to be present for several years prior to the onset of parkinsonian symptoms, received treatment with a preparation consisting of L‐dopa plus a decarboxylase inhibitor (Madopar).
Y, Herishanu, P, Rosenberg
openaire   +2 more sources

Microbiological Synthesis of L-dopa

Journal of Pharmaceutical Sciences, 1974
The ability of microorganisms to convert N-carbobenzoxyl-L-tyrosine, N-tert-butyloxycarbonyl-L-tyrosine, and N-formyl-L-tyrosine into their respective N-substituted L-dopa derivatives was studied. These tyrosine derivatives were examined because of the ease with which the blocking groups may be removed.
J, Rosazza, P, Foss, M, Lemberger, C J, Sih   +3 more
openaire   +2 more sources

Is l-dopa an endogenous neurotransmitter?

Trends in Pharmacological Sciences, 1993
Since the 1960s, L-3,4-dihydroxyphenylalanine (L-dopa), a precursor of dopamine, has been thought to occur in the cytoplasm of catecholaminergic neurones. L-Dopa is traditionally believed to be an inert amino acid that exerts actions and effectiveness in Parkinson's disease via its conversion to dopamine by L-aromatic amino acid decarboxylase.
Y, Misu, Y, Goshima
openaire   +2 more sources

Parkinsonism, L-Dopa and Intelligence

American Journal of Psychiatry, 1973
Although many patients with parkinsonism undergo a significant amount of intellectual impairment, several investigators, including the authors, have observed an improvement in intellectual functioning during the first year of treatment with L-dopa. Upon reexamining subjects after 30 months of treatment, however, the authors found that most of their ...
A W, Loranger, H, Goodell, F H, McDowell, J E, Lee, R D, Sweet   +4 more
openaire   +2 more sources

Effects of L-dopa in autism

Journal of Autism and Childhood Schizophrenia, 1971
A study was designed to determine if blood serotonin concentrations could be lowered in autistic children by the administration of L-dopa and, if so, to observe possible clinical or physiological changes. Following a 17-day placebo period, four hospitalized autistic boys (3, 4, 9, and 13 years of age) received L-dopa for 6 months.
E R, Ritvo, A, Yuwiler, E, Geller, A, Kales, S, Rashkis, A, Schicor, S, Plotkin, R, Axelrod, C, Howard   +8 more
openaire   +2 more sources

L-Dopa in the Treatment of Parkinsonism

Gerontologia Clinica, 2009
L-dopa is not the cure for parkinsonism, but it is the best drug available so far. All of our patients had other drugs before and they made further improvement on L-dopa. Toxic reactions appeared to be dose-dependent, but the patients did well on the optimum dosage (between 4 and 5 g daily in our series).
openaire   +2 more sources

Molecular conformation of L-DOPA

Biochemical and Biophysical Research Communications, 1970
Abstract The structure of L-DOPA, a biological precursor of melanins has been determined by a new systematic analysis of the Patterson function. Its molecular conformation is different from that so far reported for any aromatic aminoacid, peptide or related compound.
J W, Becker, Y T, Thathachari, P G, Simpson   +2 more
openaire   +2 more sources

L-DOPA IN IDIOPATHIC PARKINSONISM

The Lancet, 1969
Abstract Twenty-six patients with idiopathic parkinsonism were admitted to a " double blind " " within-patient " comparison between oral L-dopa and placebo. Twenty patients completed the programme. The intake of L-dopa was gradually increased to maximum tolerated dosage (1-8 g.
D B, Calne, G M, Stern, A S, Spiers, D R, Laurence   +3 more
openaire   +2 more sources